APRE Stock Price, Aprea Therapeutics Inc Quote, Chart

Market Summary

USD5.69+0.34

Delayedas of 22 Apr 2024, 11:40 am

6.36%

APRE Alerts

3 major insider buys recently.

APRE Stock Price

View Fullscreen

APRE RSI Chart

APRE Valuation

Market Cap

29.1M

Price/Earnings (Trailing)

-2.03

Price/Sales (Trailing)

49.81

Price/Free Cashflow

-2.37

APRE Price/Sales (Trailing)

APRE Profitability

Return on Equity

-84.27%

Return on Assets

-63.08%

Free Cashflow Yield

-42.24%

APRE Fundamentals

APRE Revenue

Revenue (TTM)

583.2K

APRE Earnings

Earnings (TTM)

-14.3M

Earnings Growth (Yr)

-40.99%

Earnings Growth (Qtr)

-7.45%

Breaking Down APRE Revenue

52 Week Range

2.785.75

(Low)(High)

Last 7 days

-6.3%

Last 30 days

-17.7%

Last 90 days

-0.7%

Trailing 12 Months

36.1%

How does APRE drawdown profile look like?

APRE Financial Health

Current Ratio

5.14

APRE Investor Care

Shares Dilution (1Y)

45.52%

Diluted EPS (TTM)

-3.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	583.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aprea Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	hamill john p.	acquired	-	-	3,365	srvp/cfo/prin fin & acct ofcr
Mar 28, 2024	gilad oren	acquired	-	-	6,725	president, ceo
Mar 13, 2024	henneman john b iii	bought	50,009	7.29	6,860	-
Mar 13, 2024	seizinger bernd r.	bought	50,009	7.29	6,860	-
Mar 13, 2024	gilad oren	bought	14,580	7.29	2,000	president, ceo
Mar 13, 2024	hamill john p.	bought	7,362	7.29	1,010	srvp/cfo/prin fin & acct ofcr
Aug 23, 2023	seizinger bernd r.	acquired	-	-	500	-
Aug 23, 2023	pamukcu rifat	acquired	-	-	500	-
Aug 23, 2023	grissinger michael	acquired	-	-	500	-
Aug 23, 2023	peters richard	acquired	-	-	500	-

Which funds bought or sold APRE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	NBC SECURITIES, INC.	new	-	6,000	6,000	-%
Apr 03, 2024	WealthCollab, LLC	new	-	743	743	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	533	4,700	-%
Mar 11, 2024	VANGUARD GROUP INC	added	26.87	49,118	163,034	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	1,102	10,152	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	0.03	1,740	15,280	-%
Feb 14, 2024	Walleye Capital LLC	reduced	-2.86	30,928	376,000	-%
Feb 14, 2024	Creative Planning	sold off	-100	-105	-	-%
Feb 14, 2024	Royal Bank of Canada	added	13,788	206,000	207,000	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	8,912	82,150	-%

Are Funds Buying or Selling APRE?

Are funds buying APRE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APRE

No. of Funds

APRE Alerts

3 major insider buys recently.

Unveiling Aprea Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	sio capital management, llc	7.49%	280,000	SC 13G
Feb 07, 2024	hirschman orin	9.4%	349,300	SC 13G/A
Mar 03, 2023	hirschman orin	9.2%	345,000	SC 13G
Nov 15, 2022	healthcap vii, l.p.	4.5%	2,366,104	SC 13D/A
Jun 30, 2022	healthcap vii, l.p.	10.1%	2,366,104	SC 13D/A
Feb 14, 2022	redmile group, llc	0%	0	SC 13G/A
Feb 11, 2022	versant ventures v, llc	0.0%	0	SC 13G/A
Oct 15, 2021	healthcap vii, l.p.	11.2%	2,366,104	SC 13D/A
Oct 12, 2021	morgan stanley	0.9%	184,964	SC 13G/A
Mar 24, 2021	morgan stanley	5.1%	1,072,411	SC 13G

Recent SEC filings of Aprea Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	8-K	Current Report
Apr 03, 2024	S-3	S-3
Mar 28, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to Aprea Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Aprea Therapeutics Inc News

Latest updates

Aprea Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2
Revenue	-100.0%	-	319	250
Operating Expenses	-4.0%	3,689	3,842	3,901
S&GA Expenses	-4.4%	1,643	1,720	1,699
Net Income	-7.5%	-3,443	-3,204	-3,259
Net Income Margin	-Infinity%	-24.50*	-	-
Free Cashflow	-Infinity%	-3,746	-	-3,233

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-12.1%	23.00	26.00	29.00	32.00	30.00	34.00	41.00	50.00	57.00	62.00	72.00	80.00	93.00	103	115	125	134	57.00	66.00
Current Assets	-12.2%	23.00	26.00	29.00	32.00	30.00	33.00	40.00	50.00	57.00	62.00	71.00	80.00	92.00	102	114	125	133	57.00	66.00
Cash Equivalents	-14.8%	22.00	25.00	28.00	31.00	29.00	33.00	39.00	48.00	53.00	61.00	70.00	78.00	89.00	101	113	123	130	52.00	66.00
Net PPE	2.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-	-	-	4.00	4.00	3.00	4.00	8.00	7.00	7.00	9.00	11.00	11.00	15.00	14.00	15.00	12.00	9.00	10.00	5.00
Current Liabilities	5.3%	4.00	4.00	4.00	4.00	3.00	4.00	8.00	7.00	7.00	9.00	11.00	11.00	15.00	14.00	15.00	12.00	9.00	10.00	5.00
Shareholder's Equity	-16.4%	17.00	20.00	23.00	26.00	26.00	27.00	-	44.00	50.00	53.00	61.00	69.00	77.00	89.00	100	113	124	-	-
Retained Earnings	-1.1%	-308	-304	-301	-298	-293	-291	-287	-189	-181	-173	-163	-153	-144	-128	-116	-99.93	-90.53	-77.46	-62.47
Additional Paid-In Capital	0.0%	336	336	335	335	330	328	262	243	241	237	235	233	231	230	229	227	226	20.00	20.00
Shares Outstanding	0%	4.00	4.00	4.00	4.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-
Float	-	-	-	10.00	-	-	-	14.00	-	-	-	70.00	-	-	-	264	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-66.8%	-3,739	-2,241	-3,216	-2,979	-4,020	-6,592	-8,902	-5,495	-10,178	-8,233	-7,751	-11,522	-13,199	-11,423	-9,638	-7,541	-14,742	-2,793	-4,975	-4,197	-
Cashflow From Investing	-Infinity%	-7.15	-	-	-	-	-	-	-	-	-	-	-	-16.29	725*	2.00	-12.16	-14.47	-10.25	-	-	-
Cashflow From Financing	-	-	-	-	5,140	99.00	-	-	-	1,660	-	-	-	-	-	121	30.00	91,198	-3,619	-435	5,433	-

APRE Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 583,231
Operating expenses:
Research and development	7,627,491	$ 16,402,273	$ 23,895,875
General and administrative	8,427,703	20,969,771	13,550,478
Acquired in-process research and development		76,020,184
Total operating expenses	16,055,194	113,392,228	37,446,353
Loss from operations	(15,471,963)	(113,392,228)	(37,446,353)
Other income:
Interest income, net	1,224,133	448,667	1,648
Foreign currency (loss) gain	(38,926)	281,534	317,402
Total other income	1,185,207	730,201	319,050
Net loss	(14,286,756)	(112,662,027)	(37,127,303)
Other comprehensive gain (loss):
Foreign currency translation	12,135	(264,452)	(321,695)
Total comprehensive loss	$ (14,274,621)	$ (112,926,479)	$ (37,448,998)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (3.95)	$ (67.99)	$ (34.88)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (3.95)	$ (67.99)	$ (34.88)
Weighted-average common shares outstanding, basic (in shares)	3,617,607	1,657,055	1,064,325
Weighted-average common shares outstanding, diluted (in shares)	3,617,607	1,657,055	1,064,325

APRE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 21,606,820	$ 28,786,647
Prepaid expenses and other current assets	914,275	1,366,859
Total current assets	22,521,095	30,153,506
Property and equipment, net	88,362	2,321
Restricted cash	40,717
Total assets	22,650,174	30,155,827
Current liabilities:
Accounts payable	1,670,369	842,754
Accrued expenses	2,186,262	2,358,332
Deferred grant revenue	528,974
Total current liabilities	4,385,605	3,201,086
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.001 par value, 400,000,000 shares authorized, 3,736,673 and 2,655,269 shares issued and outstanding at December 31, 2023 and 2022, respectively	3,736	2,655
Additional paid-in capital	335,644,204	330,060,836
Accumulated other comprehensive loss	(10,611,273)	(10,623,408)
Accumulated deficit	(308,083,161)	(293,796,405)
Total stockholders' equity	16,953,506	25,643,678
Total liabilities and stockholders' equity	22,650,174	30,155,827
Series A Convertible Preferred Stock
Convertible preferred stock:
Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at December 31, 2023 and 2022, respectively	$ 1,311,063	$ 1,311,063

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

CEO	Dr. Oren Gilad Ph.D.
WEBSITE	aprea.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Aprea Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aprea Therapeutics Inc? What does APRE stand for in stocks?

APRE is the stock ticker symbol of Aprea Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aprea Therapeutics Inc (APRE)?

As of Fri Apr 19 2024, market cap of Aprea Therapeutics Inc is 29.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers. The fair value of Aprea Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aprea Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APRE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aprea Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APRE is over valued or under valued. Whether Aprea Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aprea Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APRE.

What is Aprea Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, APRE's PE ratio (Price to Earnings) is -2.03 and Price to Sales (PS) ratio is 49.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APRE PE ratio will change depending on the future growth rate expectations of investors.